Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04838626 · ClinicalTrials.gov registry record · Phase 2
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 195
- Enrollment target
NCT04838626 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 195 participants.
The verdict
NCT04838626, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 195 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the diagnostic performance of \[18F\]CTT1057 as a PET imaging agent for detection and localization of PSMA positive tumors using histopathology as Standard of Truth (SoT). Tissue specimens from both the primary tumor and pelvic lymph nodes dissected during surgery from patients with newly-diagnosed high-risk prostate cancer (PCa) were used for the histopathology assessments.
Interventions
- DRUG [18F]CTT1057
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 195 participants |
| Start Date | 2021-09-07 |
| Est. Completion | 2023-11-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04838626
The ClinicalTrials.gov registry entry for NCT04838626 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 195 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [18F]CTT1057 is the first listed.
NCT04838626 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04838626 about?
NCT04838626 is a clinical study titled "Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection". The purpose of this study was to evaluate the diagnostic performance of \[18F\]CTT1057 as a PET imaging agent for detection and localization of PSMA positive tumors using histopathology as Standard of Truth (SoT). Tissue specimens from both the primary tumor and pelvic lymph nodes dissected during s...
What is the current status of trial NCT04838626?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 195 participants. The study started on 2021-09-07. Estimated completion is 2023-11-24.
What interventions are being tested in trial NCT04838626?
The interventions under investigation include: [18F]CTT1057 (DRUG).
Who is sponsoring clinical trial NCT04838626?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.